Sawyers CL - Search Results

1

Understanding Drug Sensitivity and Tackling Resistance in Cancer.

Tyner JW, Haderk F, Kumaraswamy A, Baughn LB, Van Ness B, Liu S, Marathe H, Alumkal JJ, Bivona TG, Chan KS, Druker BJ, Hutson AD, Nelson PS, Sawyers CL, Willey CD. Tyner JW, et al. Among authors: sawyers cl. Cancer Res. 2022 Apr 15;82(8):1448-1460. doi: 10.1158/0008-5472.CAN-21-3695. Cancer Res. 2022. PMID: 35195258 Free PMC article.

2

Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells.

Senechal K, Heaney C, Druker B, Sawyers CL. Senechal K, et al. Among authors: sawyers cl. Mol Cell Biol. 1998 Sep;18(9):5082-90. doi: 10.1128/MCB.18.9.5082. Mol Cell Biol. 1998. PMID: 9710592 Free PMC article.

3

Tyrosine kinase inhibitors in chronic myeloid leukemia.

Sawyers CL, Druker B. Sawyers CL, et al. Cancer J Sci Am. 1999 Mar-Apr;5(2):63-9. Cancer J Sci Am. 1999. PMID: 10198725 Review. No abstract available.

4

Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process.

Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, Said J, Reiter RE, Sawyers CL. Craft N, et al. Among authors: sawyers cl. Cancer Res. 1999 Oct 1;59(19):5030-6. Cancer Res. 1999. PMID: 10519419

5

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Druker BJ, et al. Among authors: sawyers cl. N Engl J Med. 2001 Apr 5;344(14):1031-7. doi: 10.1056/NEJM200104053441401. N Engl J Med. 2001. PMID: 11287972 Free article. Clinical Trial.

6

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Druker BJ, et al. Among authors: sawyers cl. N Engl J Med. 2001 Apr 5;344(14):1038-42. doi: 10.1056/NEJM200104053441402. N Engl J Med. 2001. PMID: 11287973 Free article. Clinical Trial.

7

Chronic myelogenous leukemia.

Druker BJ, Sawyers CL, Capdeville R, Ford JM, Baccarani M, Goldman JM. Druker BJ, et al. Among authors: sawyers cl. Hematology Am Soc Hematol Educ Program. 2001:87-112. doi: 10.1182/asheducation-2001.1.87. Hematology Am Soc Hematol Educ Program. 2001. PMID: 11722980 Review.

8

Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.

Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ, Sawyers CL, Paquette RL, O'Dwyer ME. Braziel RM, et al. Among authors: sawyers cl. Blood. 2002 Jul 15;100(2):435-41. doi: 10.1182/blood.v100.2.435. Blood. 2002. PMID: 12091333 Free article.

9

The emergence of resistance to targeted cancer therapeutics.

Mellinghoff IK, Sawyers CL. Mellinghoff IK, et al. Among authors: sawyers cl. Pharmacogenomics. 2002 Sep;3(5):603-23. doi: 10.1517/14622416.3.5.603. Pharmacogenomics. 2002. PMID: 12223047 Review.

10

Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts.

Mellinghoff IK, Tran C, Sawyers CL. Mellinghoff IK, et al. Among authors: sawyers cl. Cancer Res. 2002 Sep 15;62(18):5254-9. Cancer Res. 2002. PMID: 12234993

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

298 results

Search Page